-
Homepagina
-
Hip
-
Knee
-
Ankle
-
Shoulder
-
Elbow
-
Wrist
-
Finger
-
Data Quality
Revision per component
Knee » Survival TKA » Revision per component » Cemented primary TKA – overall revision
TABLE Cumulative revision percentages of cemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2021 (n=249,091)
Type of revision (n) | Cumulative revision percentage Kaplan Meier (95% CI) | |||||||||||||||
Femur component | Tibia component | Total primary TKAs (n) | Median (IQR) age (yr) | Total RAs (n) | Total knee (complete revision) | Patella addition | Only femur component | Only tibia component | Only insert/ patella | Missing/ unknown | 1yr | 3yr | 5yr | 7yr | 10yr | 13yr |
All cemented TKAs for osteoarthritis | 249,091 | 69 (63-76) | 10,967 | 3,839 | 2,116 | 465 | 1,000 | 3,279 | 268 | 0.9 (0.9-0.9) | 3.2 (3.1-3.3) | 4.2 (4.1-4.3) | 4.9 (4.8-5.0) | 5.7 (5.6-5.8) | 6.4 (6.3-6.6) | |
Genesis II | Genesis II | 58,842 | 69 (63-75) | 2,809 | 677 | 620 | 225 | 201 | 881 | 70 | 1.2 (1.1-1.2) | 3.9 (3.7-4.1) | 5.0 (4.8-5.2) | 5.6 (5.4-5.8) | 6.3 (6.0-6.5) | 6.8 (6.5-7.1) |
NexGen | NexGen | 55,960 | 69 (63-75) | 2,326 | 948 | 252 | 70 | 289 | 652 | 60 | 0.9 (0.8-1.0) | 2.8 (2.7-2.9) | 3.9 (3.7-4.0) | 4.8 (4.6-5.0) | 5.9 (5.6-6.1) | 6.9 (6.5-7.2) |
Vanguard Complete Knee | Vanguard Complete Knee | 44,620 | 69 (62-75) | 1,583 | 543 | 300 | 39 | 129 | 473 | 40 | 0.9 (0.8-1.0) | 2.9 (2.7-3.1) | 3.7 (3.5-3.9) | 4.2 (4.0-4.4) | 4.9 (4.6-5.2) | 5.3 (5.0-5.7) |
PFC / SIGMA | PFC / SIGMA | 30,254 | 70 (63-76) | 1,137 | 345 | 265 | 29 | 86 | 354 | 26 | 0.9 (0.8-1.0) | 3.0 (2.8-3.2) | 3.8 (3.5-4.0) | 4.1 (3.9-4.4) | 4.6 (4.3-4.9) | 4.9 (4.6-5.2) |
LCS | LCS | 17,243 | 70 (63-76) | 735 | 379 | 73 | 34 | 140 | 91 | 11 | 0.6 (0.5-0.7) | 3.1 (2.9-3.4) | 4.2 (3.8-4.5) | 4.7 (4.4-5.1) | 5.3 (4.9-5.7) | 6.0 (5.4-6.5) |
Triathlon | Triathlon | 8,852 | 70 (64-76) | 305 | 93 | 51 | 13 | 27 | 86 | 4 | 1.2 (0.9-1.4) | 3.6 (3.1-4.0) | 4.5 (3.9-5.0) | 5.1 (4.5-5.7) | 5.7 (4.9-6.5) | n.a. |
AGC V2 | AGC V2 | 4,420* | 71 (65-77) | 171 | 99 | 54 | 1 | 2 | 10 | 5 | 0.3 (0.1-0.5) | 2.0 (1.6-2.4) | 2.6 (2.1-3.1) | 3.2 (2.6-3.7) | 3.8 (3.2-4.4) | 4.7 (4.0-5.5) |
balanSys | balanSys | 3,642 | 69 (62-76) | 167 | 59 | 64 | 3 | 8 | 23 | 3 | 0.7 (0.4-1.0) | 3.7 (3.0-4.4) | 5.0 (4.2-5.8) | 5.9 (4.9-6.8) | 6.7 (5.6-7.9) | 7.9 (6.3-9.5) |
TC Plus | TC Plus | 3,456 | 70 (63-76) | 108 | 57 | 28 | 2 | 5 | 12 | 4 | 0.6 (0.3-0.8) | 2.3 (1.8-2.8) | 3.0 (2.3-3.6) | 3.3 (2.7-4.0) | 4.2 (3.3-5.1) | 4.5 (3.5-5.5) |
Attune | Attune | 3,261 | 69 (61-75) | 48 | 10 | 12 | 3 | 10 | 20 | 1 | 0.5 (0.2-0.8) | 2.4 (1.7-3.2) | 3.2 (2.2-4.1) | n.a. | n.a. | n.a. |
Optetrak | Optetrak | 3,073* | 70 (62-76) | 348 | 196 | 90 | 3 | 33 | 55 | 6 | 1.1 (0.7-1.4) | 5.3 (4.5-6.1) | 7.1 (6.2-8.0) | 9.1 (8.1-10.2) | 12.0 (10.8-13.3) | 15.3 (13.4-17.2) |
Persona | Persona | 2,909 | 68 (62-74) | 35 | 9 | 4 | 0 | 3 | 29 | 0 | 0.6 (0.3-1.0) | 3.8 (2.0-5.5) | 5.3 (3.1-7.6) | 5.9 (3.4-8.3) | n.a. | n.a. |
ACS | ACS | 2,673 | 67 (60-73) | 139 | 34 | 21 | 9 | 12 | 18 | 8 | 0.7 (0.4-1.0) | 3.8 (3.1-4.5) | 4.8 (4.0-5.6) | 5.1 (4.2-5.9) | 5.5 (4.6-6.5) | n.a. |
Scorpio NRG | Scorpio | 2,631* | 70 (63-76) | 137 | 48 | 45 | 10 | 4 | 8 | 1 | 0.8 (0.5-1.2) | 3.2 (2.5-3.8) | 4.5 (3.7-5.3) | 5.1 (4.3-6.0) | 5.7 (4.8-6.7) | n.a. |
Scorpio | Scorpio | 2,240* | 71 (63-76) | 114 | 60 | 22 | 3 | 6 | 39 | 4 | 0.3 (0.1-0.5) | 2.4 (1.7-3.0) | 3.2 (2.5-3.9) | 3.7 (2.9-4.5) | 4.7 (3.8-5.6) | 5.8 (4.7-6.9) |
Journey BCS | Journey BCS | 1,362 | 69 (61-74) | 127 | 17 | 62 | 1 | 3 | 9 | 2 | 1.1 (0.5-1.6) | 5.5 (4.2-6.8) | 6.8 (5.4-8.3) | 8.7 (7.0-10.4) | 10.8 (8.8-12.7) | 13.9 (11.2-16.5) |
MRK | MRK | 1,321 | 69 (62-75) | 22 | 10 | 7 | 0 | 0 | 7 | 1 | 0.2 (0.0-0.4) | 1.4 (0.6-2.1) | 2.2 (1.2-3.2) | 3.2 (1.8-4.7) | n.a. | n.a. |
PFC / SIGMA | LCS | 1,212* | 66 (58-75) | 54 | 27 | 11 | 3 | 1 | 2 | 2 | 0.3 (0.0-0.7) | 1.9 (1.1-2.7) | 2.9 (1.9-3.9) | 3.9 (2.8-5.1) | 4.7 (3.4-6.0) | 5.7 (4.1-7.3) |
NexGen GSF | NexGen | 1,190 | 68 (61-74) | 32 | 18 | 5 | 0 | 1 | 19 | 1 | 0.5 (0.1-0.9) | 1.6 (0.9-2.3) | 2.6 (1.7-3.6) | 2.9 (1.9-3.9) | 3.3 (2.1-4.5) | n.a. |
Innex | Innex | 1,126* | 70 (62-77) | 38 | 13 | 10 | 0 | 4 | 10 | 0 | 1.0 (0.4-1.6) | 2.2 (1.3-3.0) | 2.8 (1.8-3.8) | 3.2 (2.2-4.3) | 3.5 (2.4-4.6) | 3.6 (2.5-4.8) |
Journey II BCS | Journey BCS | 1,072 | 66 (60-72) | 64 | 13 | 26 | 0 | 0 | 6 | 2 | 0.4 (0.0-0.8) | 4.5 (3.2-5.8) | 6.1 (4.6-7.6) | 7.1 (5.3-8.9) | n.a. | n.a. |
Evolution MP | Evolution MP | 837 | 69 (63-74) | 18 | 5 | 5 | 0 | 0 | 9 | 1 | 0.6 (0.1-1.2) | 2.3 (1.1-3.5) | 3.4 (1.6-5.2) | n.a. | n.a. | n.a. |
Profix | Profix | 772* | 68 (61-76) | 59 | 40 | 7 | 2 | 2 | 5 | 1 | 0.5 (0.0-1.0) | 3.7 (2.3-5.0) | 5.6 (3.9-7.2) | 6.6 (4.8-8.3) | 7.7 (5.8-9.7) | 8.9 (6.4-11.4) |
Genesis II | Profix / Genesis MB baseplate | 622* | 67 (60-75) | 66 | 27 | 30 | 0 | 1 | 7 | 1 | 1.0 (0.2-1.8) | 6.9 (4.9-8.9) | 9.0 (6.7-11.3) | 10.3 (7.8-12.7) | 11.3 (8.7-13.8) | 11.3 (8.7-13.8) |
Rotaglide | Rotaglide | 428* | 72 (65-78) | 40 | 26 | 3 | 2 | 0 | 7 | 0 | 0.9 (0.0-1.9) | 4.5 (2.5-6.5) | 5.9 (3.7-8.2) | 7.2 (4.7-9.6) | 10.4 (7.3-13.5) | n.a. |
Advance MP | Advance | 314* | 71 (65-78) | 31 | 6 | 6 | 1 | 5 | 10 | 3 | 1.9 (0.4-3.4) | 7.7 (4.7-10.6) | 9.0 (5.8-12.1) | 9.3 (6.1-12.5) | 9.7 (6.4-12.9) | n.a. |
Maxim | Vanguard Complete Knee | 272* | 70 (63-77) | 14 | 3 | 3 | 1 | 2 | 5 | 0 | 1.5 (0.0-2.9) | 2.9 (0.9-4.9) | 3.3 (1.2-5.4) | 4.1 (1.7-6.4) | 4.8 (2.3-7.4) | 5.2 (2.6-7.8) |
* Denotes prosthesis combinations with no reported use in primary TKAs in 2021.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; RA: revision arthroplasty; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Only combinations with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
Knee » Survival TKA » Revision per component » Uncemented primary TKA – overall revision
TABLE Cumulative revision percentages of uncemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2021 (n=13,002)
Type of revision (n) | Cumulative revision percentage Kaplan Meier (95% CI) | |||||||||||||||
Femur component | Tibia component | Total primary TKAs (n) | Median (IQR) age (yr) | Total RAs (n) | Total knee (complete revision) | Patella addition | Only femur component | Only tibia component | Only insert/ patella | Missing/ unknown | 1yr | 3yr | 5yr | 7yr | 10yr | 13yr |
All uncemented TKAs for osteoarthritis | 13,002 | 69 (62-76) | 606 | 215 | 89 | 12 | 113 | 170 | 7 | 1.0 (0.8-1.2) | 3.7 (3.3-4.0) | 4.6 (4.2-5.0) | 5.1 (4.6-5.5) | 5.7 (5.2-6.2) | 6.3 (5.8-6.9) | |
LCS | LCS | 8,756 | 69 (63-76) | 387 | 109 | 44 | 9 | 90 | 110 | 4 | 0.9 (0.7-1.1) | 3.5 (3.1-3.9) | 4.2 (3.7-4.6) | 4.5 (4.1-5.0) | 5.1 (4.5-5.6) | 5.6 (4.9-6.2) |
Triathlon | Triathlon | 1,648 | 69 (62-75) | 33 | 11 | 6 | 0 | 2 | 10 | 0 | 0.5 (0.1-0.8) | 1.7 (0.9-2.4) | 2.4 (1.5-3.4) | 3.0 (1.9-4.2) | 3.4 (2.0-4.8) | n.a. |
ACS | ACS | 593 | 69 (61-75) | 30 | 11 | 6 | 1 | 4 | 5 | 0 | 2.2 (1.0-3.4) | 4.9 (3.0-6.7) | 5.4 (3.4-7.3) | 5.7 (3.6-7.8) | n.a. | n.a. |
Duracon | Duracon | 296* | 69 (61-77) | 10 | 4 | 1 | 0 | 0 | 4 | 0 | 0.4 (0.0-1.0) | 0.7 (0.0-1.7) | 1.4 (0.0-2.8) | 1.4 (0.0-2.8) | 3.1 (1.0-5.1) | 3.5 (1.2-5.7) |
Attune | Attune | 269 | 68 (62-73) | 10 | 2 | 2 | 0 | 0 | 7 | 0 | 2.2 (0.3-4.1) | 7.3 (2.6-12.1) | n.a. | n.a. | n.a. | n.a. |
Rotaglide | Rotaglide | 271* | 69 (61-77) | 61 | 38 | 11 | 1 | 1 | 5 | 1 | 1.5 (0.0-3.0) | 10.3 (6.6-14.0) | 16.3 (11.8-20.8) | 19.8 (14.8-24.7) | 21.8 (16.6-27.1) | n.a. |
ACS LD | ACS LD | 249* | 70 (61-76) | 16 | 6 | 3 | 0 | 1 | 3 | 0 | 1.3 (0.0-2.8) | 5.7 (2.7-8.7) | 5.7 (2.7-8.7) | n.a. | n.a. | n.a. |
NexGen | NexGen | 230 | 69 (62-77) | 17 | 7 | 1 | 1 | 3 | 1 | 0 | 1.8 (0.1-3.5) | 5.0 (2.1-7.9) | 7.2 (3.4-10.9) | 8.1 (4.0-12.3) | 9.3 (4.6-14.0) | n.a. |
Genesis II | Genesis II | 225 | 68 (62-75) | 11 | 5 | 2 | 0 | 1 | 1 | 1 | 1.0 (0.0-2.3) | 5.2 (2.1-8.4) | 5.2 (2.1-8.4) | 5.2 (2.1-8.4) | 5.2 (2.1-8.4) | n.a. |
Vanguard Complete Knee | Vanguard Complete Knee | 165* | 67 (61-74) | 13 | 6 | 1 | 0 | 4 | 4 | 0 | 2.6 (0.1-5.0) | 5.8 (2.1-9.5) | 5.8 (2.1-9.5) | 7.0 (2.7-11.3) | n.a. | n.a. |
* Denotes prosthesis combinations with no reported use in primary TKAs in 2021.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; RA: revision arthroplasty; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Only combinations with over 100 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
Knee » Survival TKA » Revision per component » Cemented primary TKA – major revision
TABLE Cumulative major revision percentages of cemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2021 (n=249,091)
Cumulative revision percentage Kaplan Meier (95% CI) | ||||||||||
Femur component | Tibia component | Total primary TKAs (n) | Median (IQR) age (yr) | Major revision¹ arthroplasties (n) | 1yr | 3yr | 5yr | 7yr | 10yr | 13yr |
All cemented TKAs for osteoarthritis | 249,091 | 69 (63-76) | 5,903 | 0.3 (0.3-0.4) | 1.6 (1.5-1.6) | 2.2 (2.1-2.2) | 2.6 (2.6-2.7) | 3.2 (3.1-3.3) | 3.8 (3.7-3.9) | |
Genesis II | Genesis II | 58,842 | 69 (63-75) | 1,251 | 0.4 (0.3-0.4) | 1.7 (1.5-1.8) | 2.2 (2.1-2.4) | 2.6 (2.4-2.7) | 2.9 (2.8-3.1) | 3.2 (3.0-3.4) |
NexGen | NexGen | 55,960 | 69 (63-75) | 1,430 | 0.3 (0.3-0.4) | 1.5 (1.3-1.6) | 2.2 (2.0-2.3) | 3.0 (2.8-3.1) | 3.9 (3.7-4.2) | 4.8 (4.4-5.1) |
Vanguard Complete Knee | Vanguard Complete Knee | 44,620 | 69 (62-75) | 814 | 0.4 (0.3-0.4) | 1.4 (1.3-1.5) | 1.9 (1.7-2.0) | 2.2 (2.0-2.4) | 2.6 (2.4-2.8) | 2.9 (2.6-3.2) |
PFC / SIGMA | PFC / SIGMA | 30,254 | 70 (63-76) | 521 | 0.3 (0.2-0.4) | 1.2 (1.1-1.3) | 1.7 (1.5-1.8) | 1.9 (1.7-2.1) | 2.2 (2.0-2.4) | 2.4 (2.1-2.6) |
LCS | LCS | 17,243 | 70 (63-76) | 584 | 0.4 (0.3-0.5) | 2.3 (2.1-2.6) | 3.2 (2.9-3.5) | 3.8 (3.5-4.1) | 4.4 (4.0-4.8) | 5.0 (4.5-5.5) |
Triathlon | Triathlon | 8,852 | 70 (64-76) | 148 | 0.4 (0.3-0.6) | 1.7 (1.4-2.0) | 2.3 (1.9-2.7) | 2.7 (2.2-3.1) | 2.9 (2.4-3.5) | n.a. |
AGC V2 | AGC V2 | 4,420* | 71 (65-77) | 109 | 0.1 (0.0-0.2) | 1.1 (0.8-1.4) | 1.5 (1.1-1.9) | 1.9 (1.5-2.3) | 2.4 (1.9-2.9) | 3.1 (2.5-3.7) |
balanSys | balanSys | 3,642 | 69 (62-76) | 76 | 0.2 (0.1-0.3) | 1.4 (1.0-1.8) | 2.3 (1.8-2.9) | 2.9 (2.2-3.6) | 3.2 (2.4-3.9) | 3.8 (2.6-4.9) |
TC Plus | TC Plus | 3,456 | 70 (63-76) | 71 | 0.4 (0.2-0.6) | 1.4 (1.0-1.8) | 2.0 (1.5-2.5) | 2.4 (1.8-2.9) | 2.6 (2.0-3.3) | 3.1 (2.2-4.1) |
Attune | Attune | 3,261 | 69 (61-75) | 24 | 0.2 (0.0-0.4) | 1.2 (0.6-1.7) | 1.7 (0.9-2.3) | n.a. | n.a. | n.a. |
¹ Revision of at least the femur or tibia component.
* Denotes prosthesis combinations with no reported use in primary TKAs in 2021.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
Knee » Survival TKA » Revision per component » Uncemented primary TKA – major revision
TABLE Cumulative major revision percentages of uncemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2021 (n=13,002)
Cumulative revision percentage Kaplan Meier (95% CI) | ||||||||||
Femur component | Tibia component | Total primary TKAs (n) | Median (IQR) age (yr) | Major revision¹ arthroplasties (n) | 1yr | 3yr | 5yr | 7yr | 10yr | 13yr |
All uncemented TKAs for osteoarthritis | 13,002 | 69 (62-75) | 372 | 0.6 (0.4-0.7) | 2.2 (1.8-2.5) | 2.7 (2.3-3.0) | 2.8 (2.4-3.2) | 3.0 (2.6-3.4) | 3.3 (2.8-3.8) | |
LCS | LCS | 8,446 | 69 (63-76) | 225 | 0.6 (0.4-0.7) | 2.2 (1.8-2.5) | 2.7 (2.3-3.0) | 2.8 (2.4-3.2) | 3.0 (2.6-3.4) | 3.3 (2.8-3.8) |
Triathlon | Triathlon | 1,56 | 69 (62-75) | 16 | 0.3 (0.0-0.6) | 0.7 (0.2-1.1) | 1.2 (0.5-1.9) | 1.6 (0.7-2.5) | 2.5 (1.0-4.0) | n.a. |
ACS | ACS | 573 | 69 (61-75) | 18 | 1.6 (0.6-2.7) | 3.1 (1.6-4.6) | 3.4 (1.8-4.9) | 3.7 (2.0-5.4) | n.a. | n.a. |
Duracon | Duracon | 282* | 69 (61-77) | 4 | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.4 (0.0-1.1) | 0.4 (0.0-1.1) | 1.6 (0.0-3.1) | 1.6 (0.0-3.1) |
Attune | Attune | 266 | 68 (62-73) | 2 | 0.4 (0.0-1.2) | 1.5 (0.0-3.6) | n.a. | n.a. | n.a. | n.a. |
Rotaglide | Rotaglide | 265* | 69 (61-77) | 45 | 0.4 (0.0-1.1) | 6.5 (3.5-9.5) | 11.3 (7.4-15.2) | 15.2 (10.7-19.6) | 17.3 (12.5-22.1) | n.a. |
ACS LD | ACS LD | 234* | 70 (61-76) | 8 | 1.3 (0.0-2.8) | 3.5 (1.1-5.9) | 3.5 (1.1-5.9) | n.a. | n.a. | n.a. |
NexGen | NexGen | 228 | 69 (62-77) | 12 | 1.3 (0.0-2.8) | 3.7 (1.2-6.2) | 5.0 (1.9-8.0) | 5.9 (2.4-9.5) | 5.9 (2.4-9.5) | n.a. |
Genesis II | Genesis II | 215 | 68 (62-75) | 6 | 0.5 (0.0-1.4) | 3.2 (0.7-5.6) | 3.2 (0.7-5.6) | 3.2 (0.7-5.6) | 3.2 (0.7-5.6) | n.a. |
Vanguard Complete Knee | Vanguard Complete Knee | 157* | 67 (61-74) | 10 | 1.9 (0.0-4.0) | 4.5 (1.2-7.8) | 4.5 (1.2-7.8) | 5.7 (1.7-9.7) | n.a. | n.a. |
¹ Revision of at least the femur or tibia component.
* Denotes prosthesis combinations with no reported use in primary TKAs in 2021.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
Knee » Survival TKA » Revision per component » Bone cement
TABLE Cumulative revision percentages of the most frequently registered types of bone cement by type of mixing system in primary total knee arthroplasties in the Netherlands in 2007-2021
Cumulative revision percentage Kaplan Meier (95% CI) | ||||||||
Bone cement | Total primary TKAs (n) | Total RAs (n) | 1yr | 3yr | 5yr | 7yr | 10yr | 13yr |
Separately packed bone cement components | 178,368 | 8,374 | 0.9 (0.9-0.9) | 3.3 (3.2-3.4) | 4.3 (4.2-4.4) | 5.0 (4.9-5.1) | 5.8 (5.7-6.0) | 6.5 (6.4-6.7) |
Palacos R+G | 132,927 | 6,149 | 0.9 (0.9-1.0) | 3.3 (3.2-3.4) | 4.3 (4.2-4.4) | 5.0 (4.9-5.1) | 5.8 (5.7-6.0) | 6.5 (6.3-6.8) |
Refobacin Bone Cement R | 12,700 | 610 | 0.8 (0.6-0.9) | 3.0 (2.7-3.3) | 4.0 (3.6-4.4) | 5.1 (4.7-5.6) | 6.4 (5.9-7.0) | 7.4 (6.7-8.1) |
Palacos MV+G | 8,162 | 356 | 0.8 (0.6-1.0) | 3.1 (2.7-3.4) | 4.1 (3.6-4.5) | 4.8 (4.3-5.3) | 5.2 (4.6-5.7) | n.a. |
Simplex ABC EC | 5,368* | 349 | 1.0 (0.8-1.3) | 3.9 (3.4-4.4) | 5.2 (4.6-5.8) | 6.2 (5.6-6.9) | 7.2 (6.5-8.0) | n.a. |
Simplex ABC Tobra | 5,121 | 219 | 0.8 (0.5-1.0) | 2.2 (1.8-2.6) | 3.0 (2.6-3.5) | 3.6 (3.1-4.2) | 4.7 (4.0-5.4) | 5.8 (4.7-6.9) |
Refobacin Plus Bone Cement | 3,155* | 197 | 1.1 (0.7-1.4) | 4.3 (3.6-5.1) | 5.4 (4.6-6.2) | 5.9 (5.1-6.7) | 6.4 (5.5-7.3) | 6.8 (5.9-7.8) |
Palacos R | 1,751* | 778 | 0.6 (0.2-0.9) | 2.6 (1.8-3.4) | 3.3 (2.4-4.1) | 3.9 (3.0-4.8) | 4.6 (3.6-5.6) | 5.2 (3.9-6.5) |
Biomet Plus Bone Cement | 1,472 | 64 | 1.0 (0.5-1.5) | 3.5 (2.6-4.5) | 4.5 (3.4-5.6) | 4.8 (3.6-6.0) | 5.2 (3.9-6.5) | n.a. |
Palamed G | 1,429* | 57 | 0.2 (0.0-0.4) | 2.3 (1.5-3.0) | 3.1 (2.2-4.1) | 3.5 (2.6-4.5) | 4.0 (3.0-5.0) | 4.2 (3.1-5.2) |
Subiton G | 1,161 | 34 | 1.0 (0.4-1.5) | 5.3 (3.2-7.4) | n.a. | n.a. | n.a. | n.a. |
Versabond | 647* | 50 | 0.6 (0.0-1.2) | 5.3 (3.6-7.0) | 6.3 (4.4-8.1) | 6.8 (4.8-8.7) | 7.3 (5.3-9.4) | n.a. |
cemSys 1G | 636* | 43 | 1.4 (0.5-2.3) | 3.8 (2.3-5.3) | 6.3 (4.4-8.2) | 7.4 (5.1-9.6) | n.a. | n.a. |
Biomet Bone Cement R | 598 | 20 | 0.9 (0.0-1.7) | 4.7 (2.3-7.2) | 6.3 (3.1-9.6) | 7.3 (3.5-11.0) | 7.3 (3.5-11) | n.a. |
Simplex P | 409* | 21* | 0.0 (0.0-0.0) | 2.8 (1.2-4.4) | 3.8 (1.9-5.7) | 4.4 (2.3-6.4) | 5.3 (3-7.5) | 5.6 (3.3-8.0) |
Simplex HV | 382 | 8 | 0.8 (0.0-1.7) | 2.5 (0.4-4.5) | 3.7 (0.5-6.8) | n.a. | n.a. | n.a. |
Synicem1G | 339* | 12 | 0.6 (0.0-1.4) | 3.6 (1.6-5.6) | n.a. | n.a. | n.a. | n.a. |
Palamed | 250* | 14 | 0.8 (0.0-1.9) | 2.8 (0.8-4.8) | 4.0 (1.6-6.4) | 4.9 (2.2-7.5) | 5.3 (2.5-8.1) | 5.3 (2.5-8.1) |
Bone cement pre-packed in a vacuum mixing system | 79,886 | 2,658 | 1.0 (0.9-1.1) | 3.3 (3.2-3.5) | 4.2 (4.0-4.3) | 4.8 (4.6-5.0) | 5.5 (5.2-5.8) | 6.4 (5.8-6.9) |
Refobacin Bone Cement R | 35,885 | 1,206 | 1.1 (1.0-1.2) | 3.3 (3.0-3.5) | 4.2 (3.9-4.5) | 5.0 (4.6-5.3) | 5.6 (5.2-6.0) | n.a. |
Palacos R+G | 26,935 | 723 | 1.1 (1.0-1.2) | 3.4 (3.1-3.7) | 4.1 (3.8-4.4) | 4.5 (4.1-5.0) | n.a. | n.a. |
Refobacin Plus Bone Cement | 15,254 | 620 | 0.7 (0.6-0.9) | 3.2 (2.9-3.5) | 4.0 (3.6-4.3) | 4.5 (4.1-4.9) | 5.2 (4.7-5.6) | 6.0 (5.2-6.7) |
Cemex Genta | 1,444* | 95 | 1.0 (0.5-1.6) | 4.9 (3.8-6.0) | 5.6 (4.4-6.8) | 6.3 (5.0-7.6) | 7.0 (5.6-8.5) | n.a. |
* Denotes types of bone cement with no reported use in primary TKAs in 2021.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; RA: revision arthroplasy; CI: confidence interval; IQR: interquartile range.
© LROI 2023
Only types of bone cement with over 250 procedures have been listed.
Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure of the prosthesis may have influenced the cumulative revision percentages.
ODEP rating
Orthopaedic Data Evaluation Panel. ODEP provides ratings for hip femoral stems, hip acetabular cups and total knee replacement implants. An ODEP rating consists of a number and a letter (A or B), and a star (optional). The number represents the number of years for which the product’s performance had been evidenced. The letter represents the strength of evidence presented by the manufacturer (A represents strong evidence and B represents acceptable evidence). A Star (*) represents very strong evidence above A and B. Detailed information can be found at www.odep.org.uk
Knee » Survival TKA » Revision per component » TKA by ODEP 5A or higher
FIGURE Cumulative major revision percentage of total knee arthroplasties by ODEP classification 5A or higher in the Netherlands in 2007-2021 (n= 289,912)
TABLE Cumulative 13-year revision percentage
Cumulative 13-year major revision percentage | |||
Number (n) | Competing Risk1 (95% CI) | Kaplan Meier (95% CI) | |
ODEP | |||
<5A | 40,785 | 4.2 (3.9-4.4) | 4.6 (4.3-4.9) |
5A or higher | 249,127 | 3.3 (3.2-3.4) | 3.6 (3.5-3.7) |
¹ The cumulative revision percentage using the competing risk method is shown in the figure.
Major revision percentage: First revision of the femur or tibia component, regardless of whether a minor revision has already taken place. Therefor, the first three revision procedures were reviewed.
ODEP rating: ODEP provides ratings for hip femoral stems, hip acetabular cups and total knee replacement implants. Detailed information can be found at www.odep.org.uk.
Please note: Dotted lines represent the upper and lower limits of the 95% confidence interval.
TKA: total knee arthroplasty; CI: confidence interval.
© LROI 2022
Knee » Survival TKA » Revision per component » TKA by type of femur
FIGURE Cumulative major revision percentage of total knee arthroplasties by prosthesis design in the Netherlands in 2007-2021 (n=288,993)
TABLE Cumulative 13-year major revision percentage
Cumulative 13-year major revision percentage | |||
Number (n) | Competing Risk1 (95% CI) | Kaplan Meier (95% CI) | |
Prosthesis design | |||
Posterior stabilised (PS) | 150,765 | 4.0 (3.9-4.2) | 4.4 (4.2-4.6) |
Cruciate retaining (CR) | 138,228 | 3.1 (3.0-3.3) | 3.4 (3.2-3.5) |
¹ The cumulative revision percentage using the competing risk method is shown in the figure.
Major revision percentage: First revision of the femur or tibia component, regardless of whether a minor revision has already taken place. Therefor, the first three revision procedures were reviewed.
Please note: Dotted lines represent the upper and lower limits of the 95% confidence interval.
TKA: total knee arthroplasty; PS: posterior stabilised; CR: cruciate retaining; CI: confidence interval.
© LROI 2022